N-acetyl-cysteine (NAC) is a powerful antioxidant known for scavenging free radicals, the molecules responsible for oxidative stress. Given its role in combating oxidative stress, NAC is a popular supplement for managing chronic fatigue syndrome (ME/CFS). But how effective is it, and is it the best choice for this condition? Let’s dive into the research and practical applications of NAC for ME/CFS.

What is NAC, and Why is it Important?

NAC has been around for decades, both as a supplement and a pharmaceutical. It is listed on the World Health Organization’s (WHO) Model List of Essential Medicines and is commonly used for:

• Acetaminophen Overdose: Administered intravenously to protect the liver.

• Mucus Clearance: Historically prescribed as a nebulized mucolytic for chronic bronchitis.

• Heavy Metal Chelation: Effective in binding and removing mercury, lead, and arsenic.

While NAC is widely recognized for its antioxidant properties, it is also a precursor to glutathione, one of the body’s most potent antioxidants. However, its role in boosting glutathione levels is complex, as this process depends on the availability of other amino acids (glycine and glutamate) and enzymatic efficiency.

NAC vs. Glutathione: What’s the Difference?

Though often marketed as a glutathione precursor, NAC does not directly translate into higher glutathione levels. In fact, studies have shown mixed results:

• A small clinical trial on Parkinson’s disease patients using 6,000 mg/day of NAC over a month raised cysteine levels but did not significantly improve oxidative stress markers or brain glutathione levels.

• Some trials indicate increased blood glutathione with NAC supplementation, but these effects are inconsistent.

This variability suggests that NAC is most effective when addressing clear deficiencies or severe oxidative stress.

Food Sources of NAC and Cysteine

While NAC is available in certain foods, the amounts are small and often degraded during cooking. Foods rich in cysteine, which the body can convert into NAC, include:

• Animal Products: Pork, beef, chicken, fish, and eggs.

• Plant-Based Sources: Lentils, sunflower seeds, oatmeal, and asparagus.

For example, 6 oz of meat can provide up to 595 mg of cysteine, a significant dietary source.

NAC for ME/CFS: What Does the Research Say?

Research on NAC specifically for ME/CFS is limited but intriguing:

• A 2016 pilot study from Weill Cornell found that 1,800 mg/day of NAC over four weeks increased brain glutathione levels by 15% and improved subjective symptoms.

• In vitro studies suggest that NAC can restore red blood cell glutathione levels by up to 15%, a potentially important finding given recent research showing structural abnormalities in ME/CFS red blood cells.

These findings indicate NAC may support oxidative stress reduction in ME/CFS, but robust clinical trials are lacking.

Emerging Evidence: NAC in Long-haul COVID

While studies specifically targeting NAC for long-haul COVID are limited, its longstanding safety profile and known mechanisms of action provide a strong rationale for its use. A few early clinical trials and case studies have begun to explore the benefits of NAC for long-haul COVID patients, focusing on its role in reducing fatigue, respiratory symptoms, and neuroinflammation. It is under study for potential treatment of microclots and lung damage due to COVID-19 infection. Results so far are promising but require validation in larger, well-designed studies.

The Problem with NAC: Low Bioavailability

One of NAC’s biggest limitations is its poor bioavailability. Studies have shown that only 6–10% of orally ingested NAC is absorbed, and taking it with food reduces absorption further. This means that high doses (1,800–3,600 mg/day) are often required for therapeutic effects.

Newer formulations, like N-acetylcysteine amide (NACA), may solve this problem. NACA has significantly better bioavailability, readily crosses the blood-brain barrier, and restores glutathione levels in red blood cells by up to 91% in studies. While not yet widely available, it represents a promising future for NAC supplementation.

How to Supplement with NAC

Dosage:

• Therapeutic Dose: At least 1,800 mg/day for chronic conditions like ME/CFS.

• Tolerability: Studies have shown no significant side effects at doses up to 3,600 mg/day.

Best Practices:

• Take NAC on an empty stomach to enhance absorption.

• Consider newer formulations like NACA when they become available for better efficacy.

Is NAC Right for You?

NAC is generally safe and well-tolerated, making it a reasonable option for individuals with oxidative stress or glutathione deficiencies. While evidence specifically for ME/CFS is limited, its role in supporting mitochondrial health and red blood cell function suggests potential benefits.

Be cautious of the limitations of oral NAC and stay informed about advances in formulations like NACA, which may unlock its full therapeutic potential.

Key Takeaways

• Pros: NAC is a potent antioxidant, supports glutathione production, and may help reduce oxidative stress in ME/CFS.

• Cons: Low bioavailability means high doses are necessary

Bottom Line

NAC (N-acetyl-cysteine) has been a go-to supplement for decades due to its antioxidant properties, ability to address oxidative stress, and its role as a precursor to glutathione. While the evidence specific to ME/CFS is limited, the theoretical benefits—such as restoring glutathione, improving red blood cell deformity, and mitigating oxidative damage—make it worth exploring, particularly in individuals with clear oxidative stress markers or suspected glutathione deficiency.

The key challenges are NAC's poor bioavailability and the inconsistency in study results. Newer forms like NACA (N-acetylcysteine amide) show promise in overcoming these challenges, potentially opening new doors for therapeutic use in ME/CFS and related conditions. Until such formulations become widely available, doses of 1800 mg or more of regular NAC may provide benefits, especially for those dealing with chronic fatigue, oxidative stress, or conditions with suspected glutathione depletion.

As always, consult a healthcare provider before starting any new supplement, especially at high doses. Be mindful of emerging formulations that may offer enhanced effectiveness and more reliable results in the future.

References

Šalamon, S. et al (2019) Medical and Dietary Uses of N-Acetylcysteine. Antioxidants (Basel). 8(5): 111.

Atkuri KR et al. (2007) N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 7(4):355-9.

Mokhtari, V. et al. (2017) A Review on Various Uses of N-Acetyl Cysteine. Cell J.; 19(1): 11–17.

Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008). N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opinion on Biological Therapy, 8(12), 1955–1962.

Minich D & Brown B (2019) A Review of Dietary (Phyto)Nutrients for Glutathione Support. Nutrients; 11, 2073; doi:10.3390/nu11092073

Olsson, B., Johansson, M., Gabrielsson, J., & Bolme, P. (1988). Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. European Journal of Clinical Pharmacology, 34(1), 77–82.

Sunitha K et al. (2013) N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine. Free Radic Res; 47(5):357-67.

Di Marco F, Foti G, Corsico AG. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19?. Eur Rev Med Pharmacol Sci. 2022;26(2):715-721. doi:10.26355/eurrev_202201_27898

Shungu DC et al. (2012) Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed; 25(9):1073-87.